# Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer

> **NCT07689851** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 60 (estimated)

## Conditions studied

- Gastric Cancer (GC)
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** COPOX
- **RADIATION:** Radiotherapy
- **BIOLOGICAL:** SHR-1701

## Key facts

- **NCT ID:** NCT07689851
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-07-30
- **Final completion:** 2029-07-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07689851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07689851, "Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07689851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*